Literature DB >> 28084206

Diabetes and Tuberculosis.

Blanca I Restrepo1.   

Abstract

The increase in type 2 diabetes mellitus (DM) patients in countries where tuberculosis (TB) is also endemic has led to the reemerging importance of DM as a risk factor for TB. DM causes a 3-fold increase in TB risk and a 2-fold increase in adverse TB treatment outcomes. Given the sheer numbers of DM patients worldwide, there are now more TB patients with TB-DM comorbidity than TB-HIV coinfection. There is an urgent need to implement strategies for TB prevention and control among the millions of DM patients exposed to Mycobacterium tuberculosis. This chapter summarizes the current epidemiological, clinical, and immunological knowledge on TB and DM and their clinical and public health implications. These include the underlying mechanisms for TB risk in DM patients and their clinical and sociodemographic characteristics that distinguish them from TB patients without DM. TB-DM comorbidity is posing a new challenge for integrating the short-term care for TB with the long-term care for DM, particularly in low- and middle-income countries.

Entities:  

Mesh:

Year:  2016        PMID: 28084206      PMCID: PMC5240796          DOI: 10.1128/microbiolspec.TNMI7-0023-2016

Source DB:  PubMed          Journal:  Microbiol Spectr        ISSN: 2165-0497


  83 in total

1.  Tuberculosis-diabetes epidemiology in the border and non-border regions of Tamaulipas, Mexico.

Authors:  Bassent E Abdelbary; Moncerrato Garcia-Viveros; Horacio Ramirez-Oropesa; Mohammad H Rahbar; Blanca I Restrepo
Journal:  Tuberculosis (Edinb)       Date:  2016-09-28       Impact factor: 3.131

2.  Diminished systemic and antigen-specific type 1, type 17, and other proinflammatory cytokines in diabetic and prediabetic individuals with latent Mycobacterium tuberculosis infection.

Authors:  Nathella Pavan Kumar; Parakkal Jovvian George; Paul Kumaran; Chandra Kumar Dolla; Thomas B Nutman; Subash Babu
Journal:  J Infect Dis       Date:  2014-06-06       Impact factor: 5.226

3.  The risk of tuberculosis disease among persons with diabetes mellitus: a prospective cohort study.

Authors:  Meghan A Baker; Hsien-Ho Lin; Hsing-Yi Chang; Megan B Murray
Journal:  Clin Infect Dis       Date:  2012-01-11       Impact factor: 9.079

4.  Hypodense alveolar macrophages in patients with diabetes mellitus and active pulmonary tuberculosis.

Authors:  C H Wang; C T Yu; H C Lin; C Y Liu; H P Kuo
Journal:  Tuber Lung Dis       Date:  1999

5.  Metformin as adjunct antituberculosis therapy.

Authors:  Amit Singhal; Liu Jie; Pavanish Kumar; Gan Suay Hong; Melvin Khee-Shing Leow; Bhairav Paleja; Liana Tsenova; Natalia Kurepina; Jinmiao Chen; Francesca Zolezzi; Barry Kreiswirth; Michael Poidinger; Cynthia Chee; Gilla Kaplan; Yee Tang Wang; Gennaro De Libero
Journal:  Sci Transl Med       Date:  2014-11-19       Impact factor: 17.956

6.  Drug-resistant tuberculosis in Taipei, 1996-1999.

Authors:  P D Wang; R S Lin
Journal:  Am J Infect Control       Date:  2001-02       Impact factor: 2.918

7.  Diabetic control and risk of tuberculosis: a cohort study.

Authors:  Chi C Leung; Tai H Lam; Wai M Chan; Wing W Yew; Kin S Ho; Gabriel M Leung; Wing S Law; Cheuk M Tam; Chi K Chan; Kwok C Chang
Journal:  Am J Epidemiol       Date:  2008-04-08       Impact factor: 4.897

8.  Effect of age on presentation with diabetes: Comparison of nondiabetic patients with new smear-positive pulmonary tuberculosis patients.

Authors:  Jagdish Rawat; Girish Sindhwani; Debasish Biswas
Journal:  Lung India       Date:  2011-07

9.  Impact of diabetes and smoking on mortality in tuberculosis.

Authors:  George W Reed; Hongjo Choi; So Young Lee; Myungsun Lee; Youngran Kim; Hyemi Park; Jongseok Lee; Xin Zhan; Hyeungseok Kang; SooHee Hwang; Matthew Carroll; Ying Cai; Sang-Nae Cho; Clifton E Barry; Laura E Via; Hardy Kornfeld
Journal:  PLoS One       Date:  2013-02-28       Impact factor: 3.240

Review 10.  Diabetes mellitus increases the risk of active tuberculosis: a systematic review of 13 observational studies.

Authors:  Christie Y Jeon; Megan B Murray
Journal:  PLoS Med       Date:  2008-07-15       Impact factor: 11.069

View more
  40 in total

1.  The impact of diabetes mellitus on the anti-tuberculosis treatment outcome: a series of cases from the Republic of Moldova.

Authors:  Evelina Lesnic; Alina Malic; Ovidiu Tafuni
Journal:  Med Pharm Rep       Date:  2021-07-29

2.  L-GSH Supplementation in Conjunction With Rifampicin Augments the Treatment Response to Mycobacterium tuberculosis in a Diabetic Mouse Model.

Authors:  Abrianna Beever; Nala Kachour; James Owens; Kayvan Sasaninia; Afsal Kolloli; Ranjeet Kumar; Santhamani Ramasamy; Christina Sisliyan; Wael Khamas; Selvakumar Subbian; Vishwanath Venketaraman
Journal:  Front Pharmacol       Date:  2022-06-24       Impact factor: 5.988

3.  The Effect of Diabetes and Prediabetes on Antituberculosis Treatment Outcomes: A Multicenter Prospective Cohort Study.

Authors:  María B Arriaga; Mariana Araújo-Pereira; Beatriz Barreto-Duarte; Betânia Nogueira; Maria Vitória C N S Freire; Artur T L Queiroz; Moreno M S Rodrigues; Michael S Rocha; Alexandra B Souza; Renata Spener-Gomes; Anna Cristina C Carvalho; Marina C Figueiredo; Megan M Turner; Betina Durovni; José R Lapa-E-Silva; Afrânio L Kritski; Solange Cavalcante; Valeria C Rolla; Marcelo Cordeiro-Santos; Timothy R Sterling; Bruno B Andrade
Journal:  J Infect Dis       Date:  2022-02-15       Impact factor: 7.759

4.  Mycobacterial Growth Inhibition Assay (MGIA) as a Host Directed Diagnostic Tool for the Evaluation of the Immune Response in Subjects Living With Type 2 Diabetes Mellitus.

Authors:  Miriam Bobadilla-Del-Valle; Francisco Leal-Vega; Pedro Torres-Gonzalez; Anabel Ordaz-Vazquez; Maria de Lourdes Garcia-Garcia; Ma de Los Angeles Tovar-Vargas; Guadalupe Delgado-Sanchez; Paola Del Carmen Guerra De Blas; Robert S Wallis; Alfredo Ponce-De-León; José Sifuentes-Osornio
Journal:  Front Cell Infect Microbiol       Date:  2021-05-18       Impact factor: 5.293

5.  Integrating tuberculosis and noncommunicable diseases care in low- and middle-income countries (LMICs): A systematic review.

Authors:  Chuan De Foo; Pami Shrestha; Leiting Wang; Qianmei Du; Alberto L García-Basteiro; Abu Saleh Abdullah; Helena Legido-Quigley
Journal:  PLoS Med       Date:  2022-01-18       Impact factor: 11.069

6.  BCG vaccination reduces the mortality of Mycobacterium tuberculosis-infected type 2 diabetes mellitus mice.

Authors:  Rajesh Kumar Radhakrishnan; Ramya Sivangala Thandi; Deepak Tripathi; Padmaja Paidipally; Madeline Kay McAllister; Sachin Mulik; Buka Samten; Ramakrishna Vankayalapati
Journal:  JCI Insight       Date:  2020-03-12

Review 7.  Clinical and pharmacological hallmarks of rifapentine's use in diabetes patients with active and latent tuberculosis: do we know enough?

Authors:  Chunlan Zheng; Xiufen Hu; Li Zhao; Minhui Hu; Feng Gao
Journal:  Drug Des Devel Ther       Date:  2017-10-11       Impact factor: 4.162

8.  Effects of Oral Liposomal Glutathione in Altering the Immune Responses Against Mycobacterium tuberculosis and the Mycobacterium bovis BCG Strain in Individuals With Type 2 Diabetes.

Authors:  Kimberly To; Ruoqiong Cao; Aram Yegiazaryan; James Owens; Timothy Nguyen; Kayvan Sasaninia; Charles Vaughn; Mohkam Singh; Edward Truong; Albert Medina; Edith Avitia; Jose Villegas; Christal Pham; Airani Sathananthan; Vishwanath Venketaraman
Journal:  Front Cell Infect Microbiol       Date:  2021-06-03       Impact factor: 5.293

9.  Evaluation of point-of-care algorithms to detect diabetes during screening for latent TB infection.

Authors:  A Largen; A Ayala; R Khurana; D J Katz; T K Venkatappa; R Brostrom
Journal:  Int J Tuberc Lung Dis       Date:  2021-07-01       Impact factor: 3.427

Review 10.  The Effects of Type 2 Diabetes Mellitus on Organ Metabolism and the Immune System.

Authors:  Gholamreza Daryabor; Mohamad Reza Atashzar; Dieter Kabelitz; Seppo Meri; Kurosh Kalantar
Journal:  Front Immunol       Date:  2020-07-22       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.